CC
CCCC icon

Centiva Capital’s C4 Therapeutics CCCC Stock Holding History

Centiva Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,549
Closed -$52K – 1661
2023
Q1 		$52K Buy
+16,549
New +$97.4K ﹤0.01% 1378

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Centiva Capital's CCCC Position: Q2 2023 in Review

Centiva Capital sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 16,549 shares — an estimated $52K sold.

Centiva Capital first reported a position in CCCC in Q1 2023 and held it in 1 quarter. The position peaked at $52K in Q1 2023. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Centiva Capital reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 16,549 C4 Therapeutics shares in Q2 2023, an estimated $52K.
  • Centiva Capital first reported a position in C4 Therapeutics in Q1 2023 and held it in 1 quarter.
  • Centiva Capital's C4 Therapeutics position peaked at $52K in Q1 2023.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.